Overview

6-week Safety and PD Study in Adults With NAFLD

Status:
Completed
Trial end date:
2018-04-27
Target enrollment:
Participant gender:
Summary
IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer